MetLife, Inc. (MET)
NYSE · Financials · market cap 53.21B
Share price
$97.23
At the last nightly close
Intrinsic value
n/a
No valuation the available data can support for this company.
Margin of safety
n/a
Requires an intrinsic value and a price.
EV / EBIT
n/a
Not ranked: financial sector.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.
The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2025-FY | 75.65B | 5.72B | 3.38B | 4.84 | n/a |
| 2024-FY | 70.13B | 6.66B | 4.43B | 6.13 | n/a |
| 2023-FY | 67.93B | 3.21B | 1.58B | 1.81 | n/a |
| 2022-FY | 67.41B | 7.30B | 5.28B | 3.02 | n/a |
| 2021-FY | 68.70B | n/a | 6.86B | 7.65 | n/a |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on MET.
Run the board on MET10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.